Gemiclop ASP 75/75 Tablet

AboutGemiclop ASP 75/75 Tablet is a combination of Clopidogrel 75mg and Aspirin 75mg used to prevent blood clots and reduce cardiovascular events in patients with coronary artery disease, recent heart attack, stroke, or after coronary stenting.Usage Instructions: Take once daily at the same time, with or without food. Swallow whole with water; do not crush or chew. Take with food to reduce stomach upset. Continue even if feeling well. Do not stop suddenly without medical advice (increased clot risk, especially after stenting). Take consistently at the same time daily.Benefits: Provides dual antiplatelet therapy (DAPT) with lower aspirin dose, prevents arterial thrombosis more effectively than monotherapy, reduces risk of cardiovascular death, non-fatal MI, and stroke, prevents stent thrombosis after PCI with stenting (bare-metal or drug-eluting), manages acute coronary syndrome (STEMI, NSTEMI, unstable angina), treats symptomatic peripheral arterial disease, reduces need for multiple pills and improves long-term compliance.How it Works: Clopidogrel is a prodrug irreversibly converted to active metabolite by hepatic CYP2C19. Active metabolite irreversibly antagonizes P2Y12 ADP receptors on platelet surface, inhibiting platelet activation and aggregation for platelet lifespan (7-10 days). Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1) in platelets, blocking thromboxane A2 synthesis and preventing platelet aggregation. Combined inhibition of ADP and thromboxane pathways provides synergistic and comprehensive platelet inhibition.Side Effects: Common: bleeding manifestations (minor: epistaxis, gum bleeding, easy bruising, petechiae; major: GI bleeding, hematuria), dyspepsia, nausea, abdominal pain, diarrhea, headache, dizziness, rash, pruritus. Serious: major bleeding (intracranial hemorrhage, GI bleeding, retroperitoneal bleeding), peptic ulcer disease with bleeding/perforation, thrombotic thrombocytopenic purpura (TTP), severe neutropenia/agranulocytosis, severe hypersensitivity reactions (anaphylaxis, angioedema, SJS/TEN), bronchospasm in aspirin-sensitive asthmatics, hepatotoxicity, Reye's syndrome in children.Safety Advice: Significantly increased bleeding risk; avoid high-risk activities, contact sports, and unnecessary invasive procedures. Inform all healthcare providers, dentists, and surgeons you are on dual antiplatelet therapy. Do not discontinue abruptly without cardiologist approval (especially within first 6-12 months after drug-eluting stent; catastrophic stent thrombosis risk). Consider gastroprotection with PPI (preferably pantoprazole) if high GI bleeding risk (age >65, prior ulcer, concomitant anticoagulants/NSAIDs/steroids). Avoid concomitant NSAIDs, other antiplatelets, or anticoagulants unless essential. Avoid omeprazole and esomeprazole (CYP2C19 inhibition reduces clopidogrel efficacy). Use extreme caution in bleeding diathesis, active peptic ulcer, severe hepatic impairment, or aspirin/NSAID allergy. Report signs of bleeding (unusual bruising, black/tarry stools, blood in urine, coughing/vomiting blood, severe headache, weakness, vision changes), severe abdominal pain, fever, or allergic reactions immediately. Not indicated in active pathological bleeding, severe hepatic impairment, or children/adolescents.Storage: Store below 25°C in original packaging. Protect from light, heat, and moisture. Keep out of reach of children. Do not use if packaging is damaged or tablets are discolored.